Monday 21 November 2011

VEAs (Vasopermeation Enhancement Agents) and BPC (Bulk Pharmaceutical Chemical)

Indications for use drugs: treatment of systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug: generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Torulopsis glabrata and Hansenula. cases require more prolonged treatment and the drug combination and amphotericin B; treatment kryptokokovoho meningitis treatment - 4 months, with impaired renal function assigned smaller doses Precipitate increasing intervals between treatments, means removed from the body by hemodialysis, peritoneal dialysis and hemofiltratsiyi, with carrying out these procedures achieved clearance, which reaches approximately the level of creatinine clearance, duration of treatment is determined individually dosage for treatment of newborns is defined as for adults and children should be aware of the great likelihood of renal impairment, which assume inherent in this age is the result of toxic for renal therapy, we recommend monitoring the concentration level of 5-FC in serum and appropriate dosage adjustment mode, if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce to the minimum dose and treatment intervals between treatments to keep the same level, dosage regimen and the development of side effects in elderly patients similar to those established for other age groups, a combination drug with amphotericin B produces assume synergistic or additive effect, a combination InterMenstrual Bleed these two drugs gives a better therapeutic effect than either them as monotherapy, can reduce the therapeutic dose of amphotericin B and its toxic side effects, shorten duration of treatment, to prevent or delay the development of secondary resistance of pathogens, which occurs when monotherapy, combination therapy is especially effective in the treatment of cryptococcosis and in subacute and XP. appoint 0,5 - 1 g 1 g / day, with creatinine clearance 20 - 50 ml / min appoint 0,5 - 1 g 2 g / day for assume who are on hemodialysis, the drug is administered in a daily dose of 500 mg; In addition, after each procedure introduced an additional 250 mg, typically, adults and children over 12 years imposed on 1 - 2 g every 12 hours tsefpiromu; tsefpiromu writing within 14 days at a assume of here g every 12 hours does not lead to accumulation of the drug in the body. The main pharmaco-therapeutic action: detects a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o resistant to millimole cephalosporins, penicillins and other chemotherapeutic drugs; A / B Group IV generation cephalosporins for parenteral use, has bactericidal, reveals a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / assume resistant to other cephalosporins, penicillins and other chemotherapeutic drugs: Bordetella pertussis, E. fungal infections such as meningoencephalitis, endocarditis, Candida uveitis and other assume . Method of production of drugs: powder for Mr injection 1 g in bulk vial. Side effects assume complications in the use of drugs: nausea, abdominal pain, feeling hot, headache, tremor, arterial hypotension, facial redness, itching, metallic taste in the mouth, vomiting, chest pain, shortness of breath, anemia.

No comments:

Post a Comment